Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Pfizer's Talzenna (talazoparib)-Xtandi (enzalutamide) combo for HRR-mutated metastatic hormone-sensitive prostate cancer based on Ph3 data
Small molecule, cancer, PARP inhibitor, prostate cancer, combination therapy, HRR mutation - Read more

Bristol Myers Squibb, Institute for Healthcare Improvement launch 3-year Cancer Collective Action Collaborative to expand trial access
Research collaboration, oncology, health equity, clinical trial access - Read more

Regeneron Pharmaceuticals secures $270M BARDA contract extension to supply Inmazeb through 2031
Supply agreement, infectious disease, antibody, BARDA, milestone payments - Read more

CasZyme, Cirena collaborate to optimize Cas12l CRISPR editing efficiency using synthetic long guide RNAs
Research collaboration, gene therapy, cell therapy, drug discovery, CRISPR - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) nearly quadruples progression-free survival in Ph3 B7-H3-targeted osteosarcoma trial
Antibody-drug conjugate, cancer, ADC, osteosarcoma, B7-H3 target - Read more

Pfizer submits FDA application for Elrexfio (elranatamab) in relapsed or refractory multiple myeloma following Ph3 win
Antibody, cancer, bispecific antibody, multiple myeloma, BCMA target - Read more

Microbiotica presents Ph1b data for MB097 targeting gut microbiome in anti-PD-1-refractory advanced melanoma
Microbiome therapy, cancer, melanoma, immune checkpoint inhibitor, anti-PD-1, combination therapy - Read more

Keymed Biosciences' CMG901 (CMG901) cuts death risk 53% in Ph3 trial for CLDN18.2-positive advanced gastric or gastroesophageal junction cancer
Antibody-drug conjugate, cancer, gastric cancer, CLDN18.2, third-line therapy - Read more

WuXi AppTec raises 2026 revenue forecast to $9.3B despite ongoing U.S. regulatory uncertainty
CRDMO, biosecurity, financial, competitive, operational - Read more

Novartis CEO maintains 5-6% annual revenue growth target despite two late-stage clinical trial failures
Small molecule, neurological, cardiovascular, strategic, financial - Read more

Corxel Pharmaceuticals to go public via SPAC merger with $300M private investment to advance GLP-1 obesity pill
Small molecule, obesity, major transaction, financial - Read more

Aspen Neuroscience plans $150M IPO, developing stem cell therapies for Parkinson's disease
Neurological, cell therapy, Parkinson's disease, iPSC, clinical-stage - Read more

Bambusa Therapeutics plans $150M IPO, developing bispecific antibodies for inflammatory diseases
Clinical-stage, bispecific antibody, immunology, inflammation, autoimmune - Read more

Hexagon Bio raises $62M Series C, advancing ADC payload mechanisms and HEX-360 Phase 1 trial
Oncology, antibody-drug conjugate, small molecule, natural products platform, clinical-stage - Read more

Eli Lilly defeats Novo's legal bid to temporarily block GLP-1 marketing claims amid ongoing lawsuit
GLP-1, metabolic disease, competitive, regulatory - Read more

Labcorp acquires Millennium Health to boost U.S. toxicology testing capabilities for chronic pain, substance use disorders
Diagnostics, chronic pain, substance use disorders, strategic, major transaction - Read more

Aptar Pharma acquires Pulmotree, expanding pulmonary drug delivery portfolio with Kolibri non-propellant inhaler platform
Pulmonary drug delivery, respiratory, strategic, major transaction - Read more

Anthropic files IPO, revealing drug R&D ambitions including molecular biology lab and pharma partnerships
AI drug discovery, multi-disease, IPO, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novartis takes $1.9B impairment hit after Avidity Biosciences del-desiran Phase 3 failure
Antibody-oligonucleotide conjugate, rare disease, major transaction, financial - Read more

Artiva Biotherapeutics cuts 94% of workforce, ends AlloNK development after two patient deaths and durability concerns
NK cell therapy, autoimmune, strategic, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here